In this study, BGA002 showed potent and specific dose-dependent downregulation of MYCN, at both the mRNA and protein levels, in MNA and MYCN-expressing SCLC cell lines, including multi-drug resistant cells. This evidence concerns the gene MYCN and small cell lung carcinoma.